Efficacy of adjunctive aripiprazole in major depressive disorder: A pooled response quartile analysis and the predictive value of week 2 early response

Daniel Casey, Kimberly K. Laubmeier, Sabrina Vogel Marler, Robert A. Forbes, Ross A. Baker

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective: To assess varying levels of response to aripiprazole adjunctive to standard antidepressant therapy (ADT) and the predictive value of an early response for a sustained response. Method: This post hoc analysis of 3 similarly designed randomized, double-blind, placebo-controlled phase 3 studies investigated the efficacy and safety of adjunctive aripiprazole to standard ADT in patients with major depressive disorder (DSM-IV-TR criteria) who had a prior inadequate response to 1-3 ADTs (CN138-139 [September 2004-December 2006], CN138-163 [June 2004-April 2006], and CN138-165 [March 2005-April 2008]). Response levels were defined as percent decreases from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score after 6 weeks of treatment, with a ≤ 25% decrease for minimal, > 25 to <50% decrease for partial, ≥ 50% to <75% decrease for moderate, and ≥ 75% decrease for a robust response to treatment. Results: More patients receiving adjunctive aripiprazole exhibited a partial (23.9% vs 17.9%, P =.017), moderate (23.1% vs 15.0%, P

Original languageEnglish (US)
JournalPrimary Care Companion to the Journal of Clinical Psychiatry
Volume14
Issue number3
DOIs
StatePublished - 2012

Fingerprint

Major Depressive Disorder
Antidepressive Agents
Therapeutics
Diagnostic and Statistical Manual of Mental Disorders
Placebos
Depression
Safety
Aripiprazole

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Efficacy of adjunctive aripiprazole in major depressive disorder : A pooled response quartile analysis and the predictive value of week 2 early response. / Casey, Daniel; Laubmeier, Kimberly K.; Marler, Sabrina Vogel; Forbes, Robert A.; Baker, Ross A.

In: Primary Care Companion to the Journal of Clinical Psychiatry, Vol. 14, No. 3, 2012.

Research output: Contribution to journalArticle

@article{a368306f9cfa45e9b4c0a3728f365fc6,
title = "Efficacy of adjunctive aripiprazole in major depressive disorder: A pooled response quartile analysis and the predictive value of week 2 early response",
abstract = "Objective: To assess varying levels of response to aripiprazole adjunctive to standard antidepressant therapy (ADT) and the predictive value of an early response for a sustained response. Method: This post hoc analysis of 3 similarly designed randomized, double-blind, placebo-controlled phase 3 studies investigated the efficacy and safety of adjunctive aripiprazole to standard ADT in patients with major depressive disorder (DSM-IV-TR criteria) who had a prior inadequate response to 1-3 ADTs (CN138-139 [September 2004-December 2006], CN138-163 [June 2004-April 2006], and CN138-165 [March 2005-April 2008]). Response levels were defined as percent decreases from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score after 6 weeks of treatment, with a ≤ 25{\%} decrease for minimal, > 25 to <50{\%} decrease for partial, ≥ 50{\%} to <75{\%} decrease for moderate, and ≥ 75{\%} decrease for a robust response to treatment. Results: More patients receiving adjunctive aripiprazole exhibited a partial (23.9{\%} vs 17.9{\%}, P =.017), moderate (23.1{\%} vs 15.0{\%}, P",
author = "Daniel Casey and Laubmeier, {Kimberly K.} and Marler, {Sabrina Vogel} and Forbes, {Robert A.} and Baker, {Ross A.}",
year = "2012",
doi = "10.4088/PCC.11m01251",
language = "English (US)",
volume = "14",
journal = "The primary care companion for CNS disorders",
issn = "1523-5998",
publisher = "Physicians Postgraduate Press Inc.",
number = "3",

}

TY - JOUR

T1 - Efficacy of adjunctive aripiprazole in major depressive disorder

T2 - A pooled response quartile analysis and the predictive value of week 2 early response

AU - Casey, Daniel

AU - Laubmeier, Kimberly K.

AU - Marler, Sabrina Vogel

AU - Forbes, Robert A.

AU - Baker, Ross A.

PY - 2012

Y1 - 2012

N2 - Objective: To assess varying levels of response to aripiprazole adjunctive to standard antidepressant therapy (ADT) and the predictive value of an early response for a sustained response. Method: This post hoc analysis of 3 similarly designed randomized, double-blind, placebo-controlled phase 3 studies investigated the efficacy and safety of adjunctive aripiprazole to standard ADT in patients with major depressive disorder (DSM-IV-TR criteria) who had a prior inadequate response to 1-3 ADTs (CN138-139 [September 2004-December 2006], CN138-163 [June 2004-April 2006], and CN138-165 [March 2005-April 2008]). Response levels were defined as percent decreases from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score after 6 weeks of treatment, with a ≤ 25% decrease for minimal, > 25 to <50% decrease for partial, ≥ 50% to <75% decrease for moderate, and ≥ 75% decrease for a robust response to treatment. Results: More patients receiving adjunctive aripiprazole exhibited a partial (23.9% vs 17.9%, P =.017), moderate (23.1% vs 15.0%, P

AB - Objective: To assess varying levels of response to aripiprazole adjunctive to standard antidepressant therapy (ADT) and the predictive value of an early response for a sustained response. Method: This post hoc analysis of 3 similarly designed randomized, double-blind, placebo-controlled phase 3 studies investigated the efficacy and safety of adjunctive aripiprazole to standard ADT in patients with major depressive disorder (DSM-IV-TR criteria) who had a prior inadequate response to 1-3 ADTs (CN138-139 [September 2004-December 2006], CN138-163 [June 2004-April 2006], and CN138-165 [March 2005-April 2008]). Response levels were defined as percent decreases from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score after 6 weeks of treatment, with a ≤ 25% decrease for minimal, > 25 to <50% decrease for partial, ≥ 50% to <75% decrease for moderate, and ≥ 75% decrease for a robust response to treatment. Results: More patients receiving adjunctive aripiprazole exhibited a partial (23.9% vs 17.9%, P =.017), moderate (23.1% vs 15.0%, P

UR - http://www.scopus.com/inward/record.url?scp=84864651737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864651737&partnerID=8YFLogxK

U2 - 10.4088/PCC.11m01251

DO - 10.4088/PCC.11m01251

M3 - Article

C2 - 23106023

AN - SCOPUS:84864651737

VL - 14

JO - The primary care companion for CNS disorders

JF - The primary care companion for CNS disorders

SN - 1523-5998

IS - 3

ER -